CDK12 inhibition reduces abnormalities in cells from patients with myotonic dystrophy and in a mouse model
(2020)
Journal Article
Ketley, A., Wojciechowska, M., Ghidelli-Disse, S., Bamborough, P., Ghosh, T. K., Morato, M. L., Sedehizadeh, S., Malik, N. A., Tang, Z., Powalowska, P., Tanner, M., Billeter-Clark, R., Trueman, R. C., Geiszler, P. C., Agostini, A., Othman, O., Bösche, M., Bantscheff, M., Rüdiger, M., Mossakowska, D. E., …Brook, J. D. (2020). CDK12 inhibition reduces abnormalities in cells from patients with myotonic dystrophy and in a mouse model. Science Translational Medicine, 12(541), Article eaaz2415. https://doi.org/10.1126/scitranslmed.aaz2415
Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Myotonic dystrophy type 1 (DM1) is an RNA-based disease with no current treatment.... Read More about CDK12 inhibition reduces abnormalities in cells from patients with myotonic dystrophy and in a mouse model.